Editorial work, processing and publication of the articles are free of charge for the authors.
Papers accepted for publication in CTT are made available on this site at no charge to readers (Open Access). The articles published in CTT are provided under the following license: Creative Commons Attribution 3.0 Unported, http://creativecommons.org/licenses/by/3.0/ Authors retain the copyright of their contributions.
Afanasyev B. V. (St. Petersburg, Russia)
Wagemaker G. (Rotterdam, Netherlands)
Zander A. R. (Hamburg, Germany)
Fehse B. (Hamburg, Germany)
Chukhlovin A. B. (St. Petersburg, Russia)
Aleynikova O. V. (Minsk, Republic of Belarus)
Borset M. (Trondheim, Norway)
Chechetkin A. V. (St. Petersburg, Russia)
Fibbe W. (Leiden, Netherlands)
Galibin O. V. (St. Petersburg, Russia)
Hölzer D. (Frankfurt a.M., Germany)
Klimko N. N. (St. Petersburg, Russia)
Kolb H.-J. (München, Germany)
Kröger N. (Hamburg, Germany)
Kulagin A. D. (St. Petersburg, Russia)
Lange C. (Hamburg, Germany)
Mamaev N. N. (St. Petersburg, Russia)
Mikhailova N. B. (St. Petersburg, Russia)
Moiseev I. S. (St. Petersburg, Russia)
Nagler A. (Tel-Aviv, Israel)
Nemkov A. S. (St. Petersburg, Russia)
Paramonov I. V. (Kirov, Russia)
Roumiantsev A. G. (Moscow, Russia)
Savchenko V. G. (Moscow, Russia)
Smirnov A. V. (St. Petersburg, Russia)
Uss A. L. (Minsk, Republic of Belarus)
Zubarovskaya L. S. (St. Petersburg, Russia)
A comprehensive mini-review by Prof. A. Zander provides novel data on mesenchymal stromal cells (MSC), with respect to their applications in practical medicine, evidence-based efficiency in various diseases, and prospects of its wider use in future.
Another review by Dr. S. Kulemzin et al. considers potential antigenic targets on the prostate cancer cells for prospective CAR-T cell therapy. The authors range them by their specificity to prostatic malignancies and expression grade.
Professor A. Kohlschütter presents his experience of enzyme replacement therapy of the CLN2 disease, a fatal lipid storage disorder. Its clinical course could be sufficiently improved by injections of the normal enzyme into the brain ventriculi.
A clinically sound article by Dr. P. Kozhokar deals with efficiency of repeated HSCT after failing engraftment of the 1st transplant and in relapsing malignancies. The authors show some benefits of this approach in terms of overall and relapse-free survival.
Clinical efficiency of immune checkpoint inhibitors in Hodgkin’s lymphoma is assessed in pediatric setting by Dr. A. Kozlov et al. They have shown sufficient clinical remission rates after Nivolumab therapy in refractory/resistant cases.
The issues of microbiota changes caused by heavy antibiotic treatment during HSCT procedure are discussed in original study by Dr. A. Spiridonova et al. including depletion of commensal microbes within 1st month posttransplant, and Klebsiella expansion at later terms.
A clinical case of the fatal parvovirus-associated hemorrhagic enteritis in a septic patient post-HSCT is presented by Dr. O. Goloshchapov et al. The case is well verified, however, the parvovirus was not traced from the beginning of this condition.
Under the Rehabilitation section, we publish an article by Dr. F. Terentiev et al. which proposes rational and individualized physical exercises for the children subjected to HSCT. These training programs have resulted into better quality of life in this group of pediatric patients.
A fundamental approach was used by Prof. S. Chechelnitskaya et al. who have detected some disturbances of postural stability in the children treated for cerebral malignancies. Oculomotor muscles proved to cause these functional alterations of eye movements.
Professor A. Yaremenko et al. have described experimental results which show high efficiency of polycaprolacton scaffolds, applied for closure and accelerated repair of maxillar defects occurring after tooth extraction.
The beneficiary effects of mesenchymal stem cells (MSC) are reported by Dr. Khademi et al. who have shown a significant alleviation of experimental anosmia and restoration of olfactory cells after injection of fat-derived MSCs.
An essay concerning nearest perspectives of gene editing and therapy is presented by Dr. K. Zakurdaeva who monitors the problems with development and implication issues of appropriate commercial gene-engineered products.
Maksim B. Khrustalev, Artem V. Tishkov, Natalia Yu. Turbina, Anna A. Maksimova
Sergey V. Kulemzin1, Andrey A. Gorchakov1,2, Aleksandr V. Taranin1,2
Polina V. Kozhokar1, Olesya V. Paina1, Anastasia S. Frolova1, Zhemal Z. Rakhmanova1, Anastasia S. Borovkova1, Elena V. Semenova1, Anna A. Osipova1, Kirill A. Ekushov1, Olga A. Slesarchuk1, Varvara N. Ovechkina1, Elena V. Babenko1, Alina A. Vitrishchak1, Boris I. Smirnov2, Ludmila S. Zubarovskaya1, Boris V. Afanasyev1
Andrey V. Kozlov, Ilya V. Kazantzev, Tatyana V. Iukhta, Polina S. Tolkunova, Darya A. Zvyagintseva, Asmik G. Gevorgian, Anton V. Malorodov, Kirill V. Lepik, Yury R. Zalyalov, Alexander N. Shvetsov, Anna V. Botina, Vadim V. Baykov, Elena V. Morozova, Yury A. Punanov, Natalya B. Mikhailova, Ludmila S. Zubarovskaya, Boris V. Afanasyev
Alexei B. Chukhlovin1, Anna A. Spiridonova2, Irina B. Baranova3, Artur P. Grigoriants3, Maria D. Vladovskaya1, Ludmila S. Zubarovskaya1, Boris V. Afanasyev1
Oleg V. Goloshchapov1, Natalia D. Ventslovayte1, Ruslana V. Klementeva1, Alexander N. Shvetsov1, Aleksandr A. Shcherbakov1, Maria O. Goloshchapova1, Vadim E. Karev2, Boris V. Afanasyev1
Alla A. Potapchuk1, Alisa G. Volkova1, Fedor V. Terentiev2, Irina G. Terentieva2, Ludmila S. Zubarovskaya1, Boris V. Afanasyev1
Serafima M. Chechelnitskaia, Vladimir N. Kasatkin, Marina A. Shurupova, Irina D. Borodina, Yurij V. Sarajkin, Aleksandr F. Karelin, Dmitrij V. Skvorcov, Aleksandra V. Baerbakh, Daria V. Zhuk, Vladislav A. Nikulin